The Lazaridis Institute for the Management of Technology Enterprises has selected 10 of the country’s most promising technology companies to participate in the fifth cohort of the Lazaridis ScaleUp Program. The institute, housed in Wilfrid Laurier University’s Lazaridis School of Business and Economics, supports Canada’s tech sector through research and programming focused on growth and innovation. Its ScaleUp Program helps companies grow globally through mentorship, programming, and access to a global network of experts.
Apply for Canadian Mission to Arab Health Conference in Dubai
AmacaThera Closes US$3.6M Seed Financing Round
RetiSpec Technology Featured in Globe and Mail
Reviewing OBIO's Primary Market Research Workshop
OBIO at MedTech Conference in Boston
This year's AdvaMed MedTech Conference in Boston was a fantastic event. OBIO was in attendance for meetings and conversations with US and global investors and strategics about what's coming up for the health science industry in Canada. There was tons of enthusiasm and interest to capitalize on as we head into 2020.
Recap: OBIO CAAP Alumni Group Dinner
Reviewing OBIO at RESI Boston
On September 10th, OBIO organized a cross-border networking event in Boston at the Consulate General of Canada. The event was supported by the Consulate General and law firms Fasken and Choate. Over 45 investors, strategics, as well as executives from high potential Canadian health science companies packed the Canada Room at the Consulate and resulted in numerous investor-company interactions.
Apply for the Genomic Applications Partnership Program (GAPP)
Ontario Genomics is pleased to announce that a new round of Genome Canada’s Genomic Applications Partnership Program (GAPP) is now open (Round 18). The program provides a unique opportunity for Receptor organizations to collaborate with an ’omics researcher, and to leverage their R&D investments with public funding.
Application deadline: October 28, 2019
Interface Biologics Announces Sale of Surface Modification Business to Evonik
Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the sale of its surface modification business to Evonik, a German based specialty chemical company with revenues in excess of €13 billion in 2018.
Venture capital has strongest first half on record, with $2.15-billion raised
FedDev Ontario announces $6.24 million investment in OBIO
FedDev Ontario is investing up to $6.24 million for the Ontario Bioscience Innovation Organization (OBIO®) to boost investment, market access and mentorship opportunities for companies across southern Ontario looking to commercialize their medical innovations.
iMerciv Accepted into CTA Silicon Valley Fall 2019 Cohort
Profound Medical Announces U.S. FDA 510(k) Clearance for TULSA-PRO®
Reviewing 'In-Licensing from Tech Transfer Offices: Terms, Tips & Impact on Investability'
On August 21st, OBIO hosted Norton Rose Fulbright’s Anthony de Fazekas (Partner, Head of Technology & Innovation) and Vanessa Grant (Partner), Lumira Ventures’ Jacki Jenuth (Partner), and University of Toronto’s Karen Temple (Commercialization Manager) who discussed practical considerations for licensing health science technologies from tech transfer offices, and how these agreements can impact a company’s future investability.
Able Innovations Named Lion's Lair Finalist
Perimeter Medical Imaging Closes Oversubscribed $C4.4M Financing
Register for the Medventions Lecture Series
Apply to the Women Founders Fund
Apply for a RBC Post-Doctoral and Graduate Fellowship
The RBC Post-Doctoral & Graduate Fellowships will support research and innovation at the University of Toronto and recognize emerging leaders who are establishing a record of research, scholarship, and impact, and exhibit the potential to make significant contributions to the body of research in the field of entrepreneurship and innovation.